8. Röllig, C. et al. Allogeneic stem-cell transplantation in patients with NPM1-mutated acute
myeloid leukemia: Results from a prospective donor versus no-donor analysis of patients after upfront
HLA typing within the SAL-AML 2003 trial. J. Clin. Oncol. 33, (2015).
9. Greiner, J. et al. Mutated regions of nucleophosmin 1 elicit both CD4 + and CD8 + T-cell
responses in patients with acute myeloid leukemia. Blood 120, 1282–1289 (2012).
10. Kuželová, K. et al. Association of HLA class I type with prevalence and outcome of patients with
acute myeloid leukemia and mutated nucleophosmin. PLoS One 13, 1–12 (2018).
11. de Propris, M. S. et al. High CD33 expression levels in acute myeloid leukemia cells carrying the
nucleophosmin (NPM1) mutation. Haematologica 10, 1548–1551 (2011).
12. Ehninger, A. et al. Distribution and levels of cell surface expression of CD33 and CD123 in acute
myeloid leukemia. Blood Cancer J 4, e218- (2014).
13. Lambert, J. et al. MRD assessed by WT1 and NPM1 transcript levels identifies distinct outcomes
in AML patients and is influenced by gemtuzumab ozogamicin. Oncotarget 5, 6280–6288 (2014).
14. Lambert, J. et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and
safety updates from the open-label, phase III ALFA-0701 trial. Haematologica 104, 113–119 (2019).